Company Overview of Cambridge Major Laboratories, Inc.
Cambridge Major Laboratories, Inc. provides chemistry outsourcing services for pharmaceutical and biotechnology industries. The company manufactures chemical/pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for preclinical, clinical, and commercial supply. It also provides process research services; solid state chemistry services, such as crystallization study, material characterization, solubility determination, salt selection, polymorph study, crystallization process development, and crystal habit optimization; and quality assurance services. In addition, the company offers analytical services, which include stability indicating methods, determination of residual s...
W130 N10497 Washington Drive
Germantown, WI 53022
Key Executives for Cambridge Major Laboratories, Inc.
Chief Information Officer and Vice President of Information Technology
Compensation as of Fiscal Year 2013.
Cambridge Major Laboratories, Inc. Key Developments
Cambridge Major Laboratories and AAIPharma Services Appoints Patrick Walsh as CEO of Merged Company
Nov 9 13
Cambridge Major Laboratories and AAIPharma Services announced the appointment of Patrick D. Walsh as the Chief Executive Officer (CEO) of the merged company. Patrick is a well-respected CEO with over 30 years of leadership experience in the pharmaceutical industry.
Cambridge Major Laboratories Appoints Mark Sawicki, as Chief Business Officer
Sep 12 13
Cambridge Major Laboratories, Inc. announced the appointment of Dr. Mark Sawicki as Chief Business Officer. With executive leadership responsibility for the global sales and marketing organization, Dr. Sawicki will focus on developing strategies and managing their execution to drive top line performance and P&L growth, as well as hold primary responsibility for all partnership opportunities in alignment with CML's overall strategic vision. Dr. Sawicki has over 15 years of experience driving results within the life science vertical. He has held key leadership positions and built highly effective sales and marketing operations in global environments. Prior to this role, Dr. Sawicki held the roles of Global Vice President, Business Development at CMC Biologics A/S, as well as Vice President, Business Development -- Europe at AMRI.
Kythera Biopharmaceuticals, Inc. Enters into Non-Exclusive Commercial Development and Supply Agreement with Cambridge Major Laboratories, Inc
Apr 5 13
KYTHERA Biopharmaceuticals, Inc. entered into a non-exclusive Commercial Development and Supply Agreement with Cambridge Major Laboratories, Inc. for the supply of deoxycholic acid drug substance for ATX-101. As it has previously reported, the company intends to establish long-term supply agreements with key suppliers, as well as with alternative suppliers in certain portions of its supply chain. As such, the company and Cambridge Major have agreed to commence a joint development project to validate Cambridge Major’s manufacturing process and to comply with the necessary current good manufacturing practice regulations for the commercial supply, testing, packaging, labeling and delivering of the drug substance. The Agreement contains customary commercial terms for drug substance supply regarding forecasting, payment, pricing, ordering, current good manufacturing practices, compliance, quality and indemnification. Commencing on the date ATX-101 is approved for use by the U.S. Food and Drug Administration, the company has agreed, subject to certain conditions, to purchase a customary minimum supply of drug substance from Cambridge Major for period of three years. The term of the Agreement runs through the fifth anniversary of final FDA approval of ATX-101. Following a pre-termination consultation, if either party determines that it is not feasible to maintain the joint development project, such party may terminate the Agreement upon 30 days’ written notice. The company may also terminate the Agreement upon 90 days’ written notice if denied regulatory approval of ATX-101 in the US, or immediately if Cambridge Major has not corrected or established a mutually agreed upon remediation plan for results which have been reasonably identified as critical by a company audit or regulatory inspection within 90 days of receipt of such audit or inspection report. The company may terminate the Agreement without cause with two year’s prior written notice following the three-year anniversary of the Effective Date, and Cambridge Major may terminate the Agreement without cause with three year’s prior written notice following the two-year anniversary of the Effective Date. The Agreement may also be terminated by either party in the event of a material breach by or insolvency of the other party.
Similar Private Companies By Industry
Recent Private Companies Transactions